XLO

7.4301.07%
DJ

Daniel J. Curran

Independent Director

Dr. Daniel J. Curran, also known as Dan, was Board Observer of Day One Biopharmaceuticals, Inc. He was an Independent Director of Catalyst Pharmaceuticals, Inc. from August 01, 2025 to July 15, 2026. Dr. Curran serves as an Independent Director of ALX Oncology Holdings Inc. since August 12, 2025. Dr. Curran is Director of Tome Biosciences, Inc. from January 2024. He is a Director of Stargazer Pharmaceuticals Inc. Mr. Dan Curran is a co-founder and Managing Partner of Mountainfield Venture Partners, LLC. Trained as a physician-scientist, he has more than several years of broad biopharmaceutical experience ranging from drug development to business development to venture investing. Prior to Mountainfield, Dan was Senior Vice President and Head of Rare Disease Therapeutic Area for Takeda Pharmaceutical Company. He served as a Director of Oak Hill Bio Corp. since February 2022. Dr. Curran served as Vice President of Business and Corporate Development at Millennium Pharmaceuticals, Inc. from June 1999 to 2008. He has been an Independent Director of Xilio Therapeutics, Inc. since December 2020 Dr. Curran has many years of pharmaceutical experience in business development, project leadership and development roles. He is the Head of the Rare Genetics and Hematology Therapeutic Area Unit (TAU) at Takeda Pharmaceutical Company Ltd. In this role, he leads Takeda’s strategy, research and development efforts to unlock innovation and deliver transformative medicines in the areas of rare genetic and hematologic diseases. He joined Millennium in 1999 as a Director of Business Development. From 1999 to 2003, he played a key role in Millennium’s business development activities and was a driving force for strategic business transactions in the inflammation and cardiovascular disease franchises. In 2003, he moved to Millennium’s research and development organization and assumed leadership for two inflammation development programs. Dr. Curran has served on the board of directors of Stargazer Pharmaceuticals, Inc. a private ophthalmic biotechnology company, since 2019. He rejoined the corporate development group in 2006 as Vice President and is responsible for strategic business transactions for Millennium. He has served as the primary negotiator of numerous transactions with pharmaceutical and biotechnology companies during his 11-year tenure at Millennium. Prior to Millennium, his previous professional experiences include a business development role in the Product Planning and Acquisition group at DuPont Merck Pharmaceuticals. Dr. Curran received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in chemistry from King’s College.

Positions